FuboTV Uplisting, Kronos Bio Highlight This Week's IPOs

This week has down with 6 IPOS scheduled for Thursday and Friday.

FuboTV: Sport first live tv streaming company Fubo TV FUBO is uplisting to the Nasdaq. The company is selling 15 million shares in a range of $9 to $11.

The company offers a package of over 100 channels, catering to sports fans, at a price point of $59.99 a month. The package includes 43 of the top 50 ranked channels.

In June, the company had 286,126 paid subscribers. Revenue for 2019 was $146.5 million, a 96% year-over-year increase.

Advertising revenue is an area of growth for the company. In 2019, advertising revenue was up 201% year-over-year to $12.5 million. Advertising revenue is expected to hit $6 to $7 per paying customer in the third quarter.

In September, Fubo announced it was seeing strong third-quarter demand from the NFL season. The company now expects paid subscribers of 370,000 to 380,000 in the third quarter.

Investors in FuboTV include Walt Disney Co DIS, Comcast Corporation CMCSA, AMC Networks AMCX and ViacomCBS VIAC

Aziyo Biologics: Offering implantable medical devices, spinal repair and soft tissue reconstruction, Aziyo Biologics AZYO is a regenerative medicine company. The stock debuted Thursday at $17.32 a share, above the $17 IPO price.

The company has commercial relationships with Boston Scientific BSX and Medtronic MDT. The company has four commercial products approved over the last three years and is counting on a robust pipeline to grow approvals and revenue.

iHuman: Childhood edutainment company iHuman IH is the largest provider in China for the category. The company has 10.3 million MAU with 1.4 million paying users.

The company has seen 222% year-over-year growth in users. iHuman revenue was $30.9 million in 2019 and $26.3 million for the first half six months of 2020.

iHuman plans to offer 7 million ADS at a price point of $11 to $13.

Spruce Biosciences: Late-stage biotechnology Spruce Biosciences SPRB plans to offer 5 million shares at a price point of $14 to $16.

The company is working on the unmet medical need for rare endocrine disorders. The company is targeting classic congenital adrenal hyperplasia with its lead candidate tildacerfront.

Novo Holdings, a unit of Novo Nordisk NVO, is the top shareholder of the company.

Kronos Bio: Clinical stage biotechnology Kronos Bio KRON plans to sell 10.3 million shares at a price point of $16 to $18.

The company’s lead product entospletinib is targeting acute myeloid leukemia with a planned Phase 2/3 trial in 2021 and data readouts in 2023.

Kronos bought the SYK Inhibitor portfolio from Gilead Sciences GILD.

Shattuck Labs: Clinical stage biotechnology Shattuck Labs STTK plans on selling 10 million shares at a price point of $14 to $16.

The company’s lead SL-172154 with a Phase I trial for ovarian cancer. A read-out is expected on this trial in the second half of 2021.

Takeda Pharmaceuticals is partnered with Shattuck on a second candidate named SL-279252 targeting solid tumors and lymphoma.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsIPOsAziyo BiologicsChinaFuboTViHumanKronos BionflNovo HoldingsShattuck LabsSpruce BiosciencesstreamingSyk inhibitorTakeda Pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!